<DOC>
	<DOCNO>NCT01240200</DOCNO>
	<brief_summary>Several study show high blood sugar ( glucose ) level associate disease cause diabetes . Controlling glucose may prevent complication . As people age , body become unable make enough insulin control blood sugar . Pills use treat diabetes may help , many time last . When blood sugar high , insulin frequently recommend use treat diabetes . Insulin often start add long-acting insulin medicine patient already take . In study , glargine insulin take together diabetes pill currently use . Glargine long-acting insulin give skin day . Glargine approve use treatment patient diabetes FDA ( Food Drug Administration ) . Currently , insulin delivery available shot . The purpose study compare satisfied patient use two different type insulin shot . Specifically , study aim determine people 65 year old satisfy take insulin shot pen syrinx . Everyone join study chance use insulin syrinx insulin pen . The ability patient give shot affect well sugar control . As people age , medical problem may develop affect ability certain thing . Another aim study determine ability use insulin pen insulin syringe affect age problem . During 25 week long study , patient treat insulin give syringe 12 week pen 12 week . Questionnaires give determine satisfaction treatment throughout study . The investigator hypothesize among elderly patient type 2 diabetes mellitus fail oral agent therapy , treatment basal insulin via pen device result higher treatment satisfaction score accurate dose treatment basal insulin via conventional vial/syringe method . A total 56 subject type 2 diabetes recruit study . The site study Grady Memorial Hospital clinic .</brief_summary>
	<brief_title>Satisfaction Treatment Among Elderly Patients With Insulin Therapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>1 . Males female age ≥65 year 2 . History type 2 diabetes &gt; 3 month duration 3 . Current use oral antidiabetic agent and/or diet treat diabetes 4 . A1c ≤10.0 % fast glucose ≤300 mg/dL 5 . A1c ≥7.0 % and/or fasting glucose ≥150 mg/dL 1 . Subjects know allergy glargine metabolites 2 . Subjects unwilling selfinject insulin 3 . Inability selfmonitor blood glucose 4 . Current previous use insulin 6 continuous month prior study enrollment 5 . Subjects document clinically relevant hepatic disease ( diagnose liver cirrhosis portal hypertension ) , corticosteroid therapy , impaired renal function ( creatinine &gt; 3.0 mg/dL ) , uncontrolled endocrine disorder associate increased insulin resistance acromegaly , Cushing 's syndrome , hyperthyroidism 6 . Mental condition render subject unable understand nature , scope and/or possible consequence study 7 . Inability unwillingness provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>diabetes</keyword>
	<keyword>elderly</keyword>
	<keyword>insulin injection</keyword>
</DOC>